Global Biosimilar Insulin Competitive Landscape Professional Research Report 2025
Description
Global Biosimilar Insulin Competitive Landscape Professional Research Report 2025
Research Summary
Biosimilar insulin is a type of insulin that is similar in structure and function to the original insulin product. Biosimilar insulins are designed to work in the same way as the branded insulin products but are produced by different manufacturers. Biosimilar insulin products have undergone extensive testing to prove that they are just as safe, effective, and reliable as the original insulin products. Biosimilar insulin is typically less expensive than the branded insulin products, which may make it more accessible for individuals who need insulin treatment.
According to DIResearch's in-depth investigation and research, the global Biosimilar Insulin market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.
The major global manufacturers of Biosimilar Insulin include Eli Lilly, Sanofi, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon, Wockhardt etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Biosimilar Insulin. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Biosimilar Insulin market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Biosimilar Insulin market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Biosimilar Insulin industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Biosimilar Insulin Include:
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Biosimilar Insulin Product Segment Include:
Biosimilar Insulin Glargine
Biosimilar Insulin Lispro
Other
Biosimilar Insulin Product Application Include:
Hospital
Retail Pharmacy
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Biosimilar Insulin Industry PESTEL Analysis
Chapter 3: Global Biosimilar Insulin Industry Porter’s Five Forces Analysis
Chapter 4: Global Biosimilar Insulin Major Regional Market Size and Forecast Analysis
Chapter 5: Global Biosimilar Insulin Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Passenger Biosimilar Insulin Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Biosimilar Insulin Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Biosimilar Insulin Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Biosimilar Insulin Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Biosimilar Insulin Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Biosimilar Insulin Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Biosimilar Insulin Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources
Table of Contents
170 Pages
- 1 Biosimilar Insulin Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Biosimilar Insulin Product by Type
- 1.2.1 Biosimilar Insulin Glargine
- 1.2.2 Biosimilar Insulin Lispro
- 1.2.3 Other
- 1.3 Biosimilar Insulin Product by Application
- 1.3.1 Hospital
- 1.3.2 Retail Pharmacy
- 1.3.3 Others
- 1.4 Global Biosimilar Insulin Market Size Analysis (2020-2032)
- 1.5 Biosimilar Insulin Market Development Status and Trends
- 1.5.1 Biosimilar Insulin Industry Development Status Analysis
- 1.5.2 Biosimilar Insulin Industry Development Trends Analysis
- 2 Biosimilar Insulin Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Biosimilar Insulin Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Biosimilar Insulin Market Analysis by Regions
- 4.1 Biosimilar Insulin Overall Market: 2024 VS 2025 VS 2032
- 4.2 Global Biosimilar Insulin Revenue and Forecast Analysis (2020-2032)
- 4.2.1 Global Biosimilar Insulin Revenue and Market Share by Region (2020-2025)
- 4.2.2 Global Biosimilar Insulin Revenue Forecast by Region (2026-2032)
- 5 Global Biosimilar Insulin Market Size by Type and Application
- 5.1 Global Biosimilar Insulin Market Size by Type (2020-2032)
- 5.2 Global Biosimilar Insulin Market Size by Application (2020-2032)
- 6 North America
- 6.1 North America Biosimilar Insulin Market Size and Growth Rate Analysis (2020-2032)
- 6.2 North America Key Manufacturers Analysis
- 6.3 North America Biosimilar Insulin Market Size by Type
- 6.4 North America Biosimilar Insulin Market Size by Application
- 6.5 North America Biosimilar Insulin Market Size by Country
- 6.5.1 US
- 6.5.2 Canada
- 7 Europe
- 7.1 Europe Biosimilar Insulin Market Size and Growth Rate Analysis (2020-2032)
- 7.2 Europe Key Manufacturers Analysis
- 7.3 Europe Biosimilar Insulin Market Size by Type
- 7.4 Europe Biosimilar Insulin Market Size by Application
- 7.5 Europe Biosimilar Insulin Market Size by Country
- 7.5.1 Germany
- 7.5.2 France
- 7.5.3 United Kingdom
- 7.5.4 Italy
- 7.5.5 Spain
- 7.5.6 Benelux
- 8 China
- 8.1 China Biosimilar Insulin Market Size and Growth Rate Analysis (2020-2032)
- 8.2 China Key Manufacturers Analysis
- 8.3 China Biosimilar Insulin Market Size by Type
- 8.4 China Biosimilar Insulin Market Size by Application
- 9 APAC (excl. China)
- 9.1 APAC (excl. China) Biosimilar Insulin Market Size and Growth Rate Analysis (2020-2032)
- 9.2 APAC (excl. China) Key Manufacturers Analysis
- 9.3 APAC (excl. China) Biosimilar Insulin Market Size by Type
- 9.4 APAC (excl. China) Biosimilar Insulin Market Size by Application
- 9.5 APAC (excl. China) Biosimilar Insulin Market Size by Country
- 9.5.1 Japan
- 9.5.2 South Korea
- 9.5.3 India
- 9.5.4 Australia
- 9.5.5 Southeast Asia
- 10 Latin America
- 10.1 Latin America Biosimilar Insulin Market Size and Growth Rate Analysis (2020-2032)
- 10.2 Latin America Key Manufacturers Analysis
- 10.3 Latin America Biosimilar Insulin Market Size by Type
- 10.4 Latin America Biosimilar Insulin Market Size by Application
- 10.5 Latin America Biosimilar Insulin Market Size by Country
- 10.5.1 Mexico
- 10.5.2 Brazil
- 11 Middle East & Africa
- 11.1 Middle East & Africa Biosimilar Insulin Market Size and Growth Rate Analysis (2020-2032)
- 11.2 Middle East & Africa Key Manufacturers Analysis
- 11.3 Middle East & Africa Biosimilar Insulin Market Size by Type
- 11.4 Middle East & Africa Biosimilar Insulin Market Size by Application
- 11.5 Middle East & Africa Biosimilar Insulin Market Size by Country
- 11.5.1 Saudi Arabia
- 11.5.2 South Africa
- 12 Competition by Manufacturers
- 12.1 Global Biosimilar Insulin Market Revenue by Key Manufacturers (2021-2025)
- 12.2 Biosimilar Insulin Competitive Landscape Analysis and Market Dynamic
- 12.2.1 Biosimilar Insulin Competitive Landscape Analysis
- 12.2.2 Global Key Manufacturers Headquarter Location and Key Area Sales
- 12.2.3 Market Dynamic
- 13 Key Companies Analysis
- 13.1 Eli Lilly
- 13.1.1 Eli Lilly Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.1.2 Eli Lilly Biosimilar Insulin Product Portfolio
- 13.1.3 Eli Lilly Biosimilar Insulin Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.2 Sanofi
- 13.2.1 Sanofi Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.2.2 Sanofi Biosimilar Insulin Product Portfolio
- 13.2.3 Sanofi Biosimilar Insulin Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.3 Gan&Lee
- 13.3.1 Gan&Lee Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.3.2 Gan&Lee Biosimilar Insulin Product Portfolio
- 13.3.3 Gan&Lee Biosimilar Insulin Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.4 Tonghua Dongbao
- 13.4.1 Tonghua Dongbao Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.4.2 Tonghua Dongbao Biosimilar Insulin Product Portfolio
- 13.4.3 Tonghua Dongbao Biosimilar Insulin Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.5 United Laboratory
- 13.5.1 United Laboratory Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.5.2 United Laboratory Biosimilar Insulin Product Portfolio
- 13.5.3 United Laboratory Biosimilar Insulin Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.6 Geropharm
- 13.6.1 Geropharm Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.6.2 Geropharm Biosimilar Insulin Product Portfolio
- 13.6.3 Geropharm Biosimilar Insulin Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.7 Biocon
- 13.7.1 Biocon Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.7.2 Biocon Biosimilar Insulin Product Portfolio
- 13.7.3 Biocon Biosimilar Insulin Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.8 Wockhardt
- 13.8.1 Wockhardt Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.8.2 Wockhardt Biosimilar Insulin Product Portfolio
- 13.8.3 Wockhardt Biosimilar Insulin Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 14 Industry Chain Analysis
- 14.1 Biosimilar Insulin Industry Chain Analysis
- 14.2 Biosimilar Insulin Industry Raw Material and Suppliers Analysis
- 14.2.1 Biosimilar Insulin Key Raw Material Supply Analysis
- 14.2.2 Raw Material Suppliers and Contact Information
- 14.3 Biosimilar Insulin Typical Downstream Customers
- 14.4 Biosimilar Insulin Sales Channel Analysis
- 15 Research Findings and Conclusion
- 16 Methodology and Data Source
- 16.1 Methodology/Research Approach
- 16.2 Research Scope
- 16.3 Benchmarks and Assumptions
- 16.4 Date Source
- 16.4.1 Primary Sources
- 16.4.2 Secondary Sources
- 16.5 Data Cross Validation
- 16.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
